Mangalam Drugs and Organics Ltd
Pharmaceuticals & Biotechnology | Small Cap
Mangalam Drugs and Organics Ltd, operating within the Healthcare Services industry, showcases a mixed financial performance. The company demonstrates notable strength in solvency and profitability. However, liquidity, efficiency, and coverage ratios reveal potential areas of concern. While the company has experienced a decline in revenue and EPS growth, its operating profit and asset growth show promise. The company's ability to manage its debts is a notable strength, but its ability to meet its short-term obligations needs improvements. Overall, the company's financial health presents a complex picture, requiring further scrutiny to leverage its strengths and address its weaknesses.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio4.00
- Financial Ratio2.40
- Profitability Ratio9.60
- Efficiency Ratio4.33
- Coverage Ratio2.00
- Solvency Ratio9.50
- Liquidity Ratio2.40
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekNeutral
- 1 MonthNeutral
Mangalam Drugs and Organics Ltd, operating within the Healthcare Services industry, showcases a mixed financial performance. The company demonstrates notable strength in solvency and profitability. However, liquidity, efficiency, and coverage ratios reveal potential areas of concern. While the company has experienced a decline in revenue and EPS growth, its operating profit and asset growth show promise. The company's ability to manage its debts is a notable strength, but its ability to meet its short-term obligations needs improvements. Overall, the company's financial health presents a complex picture, requiring further scrutiny to leverage its strengths and address its weaknesses.
Overall Valuation Score
P/E RATIO (TTM)
-1.08
Industry Median
18.24
Small Cap Median
12.96
P/E RATIO
-1.07
P/B RATIO
0.46
Industry Median
1.32
Small Cap Median
1.21
P/S RATIO
0.20
Industry Median
1.16
Small Cap Median
1.00
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-3.76
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹30.03 as on Jun 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth performance is mixed, showing strength in operating profit and asset growth. However, it has experienced declines in revenue, EPS, and net income growth. While operating profitability and asset expansion are positive signs, the negative trends in revenue and earnings raise concerns about the company's overall growth trajectory. Addressing these factors will be crucial for sustainable long-term growth.
| Growth Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue Growth Rate | -13.82 | -27.04 | |
| Operating Profit Growth Rate | 111.76 | -141.67 | |
| Earnings Per Share (EPS) Growth | -174.17 | -760 | |
| Asset Growth Rate | 9.58 | -13.93 | |
| Net Income Growth Rate | -177.78 | -728.57 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed picture. Adjusted EPS, cash EPS, book value per share, dividend per share and capital expenditures are below the expected ranges. The ratios indicate potential areas of concern regarding earnings quality, shareholder value, and investment in future growth. Addressing these issues could improve investor confidence and overall financial health.
| Financial Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | -5.62 | 4.38 | -27.5 |
| Cash Earnings Per Share (Cash EPS) | 3.75 | 15 | -16.25 |
| Book Value Per Share | 85 | 93.12 | 64.38 |
| Dividend Per Share (DPS) | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 11.8 | 19.5 | 11.7 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company demonstrates good profitability, with robust gross profit margin, ROCE, ROE, ROA, operating margin, and net margin. The company is generating profits from its capital employed, equity, and assets. Strong profitability indicates efficient operations and effective cost management. This positions the company favorably within its industry.
| Profitability Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Gross Profit Margin | 0.54 | 5.97 | -14.22 |
| Return on Capital Employed (ROCE) | 1.79 | 8 | -14 |
| Return on Equity (ROE) | -6.62 | 4.7 | -42.72 |
| Return on Assets (ROA) | 5.09 | 9.84 | -4.76 |
| Operating Margin | 4.61 | 11.32 | -6.47 |
| Net Margin | -2.44 | 2.2 | -18.97 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency in managing its assets presents a mixed picture. It shows strength in receivables turnover. However, fixed asset turnover, inventory turnover, days sales in inventory, and capital turnover are areas needing improvement. While efficient in collecting receivables, the company struggles with asset utilization and inventory management. Improving these areas could significantly enhance operational performance and profitability.
| Efficiency Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.49 | 1.95 | 1.46 |
| Inventory Turnover Ratio | 2.95 | 2.27 | 2.19 |
| Receivables Turnover Ratio | 13.04 | 9.49 | 5.87 |
| Days Sales in Inventory Ratio | 123.73 | 160.79 | 166.67 |
| Receivable Days | 28 | 38.46 | 62.18 |
| Capital Turnover Ratio | 2.2 | 1.84 | 2.05 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are weak, particularly concerning interest coverage and equity dividend coverage. The company's ability to cover its interest expenses is limited. With low coverage ratios, the company may face increased financial risk and reduced flexibility in managing its debt and dividend obligations.
| Coverage Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Interest Coverage Ratio | 0.21 | 1.33 | -2.06 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits good solvency, demonstrating a strong capacity to meet its long-term obligations. Low debt and high equity levels suggest a stable financial structure. The debt-to-asset ratio further supports this, indicating a conservative approach to leveraging assets. This financial stability provides a solid foundation for future growth and resilience against economic downturns.
| Solvency Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debt Ratio | 0.19 | 0.14 | 0.09 |
| Debt to Equity Ratio | 0.23 | 0.16 | 0.1 |
| Equity Ratio | 0.81 | 0.86 | 0.91 |
| Debt To Asset Ratio | 0.1 | 0.07 | 0.03 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, indicating potential difficulties in meeting short-term obligations. The current, quick, and cash ratios are all at concerning levels. The operating cash flow ratio offers a slight positive outlook, suggesting some ability to generate cash from operations. However, the overall low liquidity scores signal a need for improved working capital management to ensure the company can comfortably cover its immediate liabilities.
| Liquidity Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Current Ratio | 1.07 | 1.04 | 0.78 |
| Quick Ratio | 0.33 | 0.32 | 0.26 |
| Cash Ratio | 0.01 | 0.02 | 0 |
| Operating Cash Flow Ratio | 0.02 | 0.22 | 0.02 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medicamen Organics Ltd | 6.30 | -6.94 | Neutral | -3.75 | -2.50 | -4.02 |
| 2 | Mono Pharmacare Ltd | 6.16 | 6.26 | Neutral | 8.00 | 1.75 | 3.00 |
| 3 | JFL Life Sciences Ltd | 6.07 | 9.43 | Neutral | 12.00 | 1.94 | 6.00 |
| 4 | Walpar Nutritions Ltd | 5.29 | 9.26 | Neutral | 6.66 | 2.09 | 3.00 |
| 5 | Mangalam Drugs and Organics Ltd | 4.50 | -1.07 | Neutral | -15.00 | -27.68 | -44.00 |
| 6 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 7 | Sunrest Lifescience Ltd | 4.17 | 7.06 | Highly Undervalued | 10.21 | 3.60 | 8.00 |
The management effectiveness of Mangalam Drugs and Organics Ltd is mixed. The company shows operating profit margin (OPM) improvement and net profit turnaround. Declining sales growth and negative Return on Equity pose concerns. Stable promoter holding indicates confidence, but low institutional interest suggests limited external validation. Overall, management is showing improvement signs but needs to address growth challenges and manage debt levels.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Improved Profitability | 11% OPM in Mar 2025 | Improving operational efficiency |
| Stable Promoter Holding | 50.30% | Consistent promoter confidence | |
| CONS | Declining Sales Growth | -13.66% | Decreasing revenue expansion |
| Low Return on Equity | -6.15 | Poor shareholder returns |
Financial Performance & Growth
Mangalam Drugs and Organics Ltd shows mixed financial performance. Sales Growth is concerning, with a TTM of -14%. However, the Compounded Profit Growth TTM is 175%, indicating a turnaround in profitability. OPM has improved to 11% in Mar 2025 from 5% in Mar 2024. The company's quarterly results show fluctuating sales figures, highlighting volatility.
| Metric | TTM |
|---|---|
| Compounded Sales Growth | -14% |
| Compounded Profit Growth | 175% |
The inconsistent sales growth suggests potential instability in revenue streams. The improvement in profit growth and OPM, however, indicates successful cost management and operational efficiencies. Despite these improvements, the overall picture remains uncertain due to the volatile sales performance.
Capital Efficiency & Returns
The capital efficiency and returns of Mangalam Drugs and Organics Ltd are areas of concern. The ROCE is 1.23%, and ROE is -6.15%, indicating poor returns on capital and equity.
The low ROCE and negative ROE suggest that the company is not effectively utilizing its capital and shareholder funds to generate profits. This could be due to inefficient asset utilization or high operational costs.
Financial Health & Prudence
Mangalam Drugs and Organics Ltd exhibits moderate financial health. The company has Borrowings. Interest Coverage Ratio cannot be calculated due to negative profit before tax in Mar 2024, posing a risk. The company does not have Dividend Payout.
| Metric | Mar 2024 | Mar 2025 |
|---|---|---|
| Borrowings | 106 | 89 |
| Interest | 14 | 15 |
The presence of borrowings necessitates careful monitoring. The inability to calculate the Interest Coverage Ratio due to negative profit before tax is a concern, as it raises questions about the company's ability to meet its interest obligations. The absence of dividend payouts may deter some investors seeking regular income.
Shareholding & Ownership Structure
The shareholding pattern of Mangalam Drugs and Organics Ltd indicates stable promoter confidence. Promoter Holding is consistently around 50.3%. Institutional Holding by FIIs is minimal but increasing.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Promoter Holding | 50.31% | 50.31% | 50.30% |
| FIIs | 0.10% | 0.26% | 0.47% |
The stable promoter holding suggests a strong commitment from the company's founders and key stakeholders. The increasing FII interest, although still small, could indicate growing external confidence in the company's prospects.
Mangalam Drugs and Organics Ltd faces moderate risk due to segment performance volatility, declining sales, and negative Return on Equity (ROE). The increase in inventory days and cash conversion cycle indicates operational inefficiencies, and the high level of borrowings raises concerns about financial leverage.
Segment performance volatility
The company's quarterly results reveal fluctuations in sales and profit margins, indicating segment performance volatility. The inconsistency in YOY Sales Growth % and YOY Profit Growth % across different quarters.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1029.97Bullish
- SMA 2030.03Bullish
- SMA 5029.37Bullish
- EMA 1029.93Bullish
- EMA 2029.89Bullish
- EMA 5029.55Bullish
- DEMA 1029.90Bullish
- DEMA 2030.06Bullish
- DEMA 5030.01Bullish
- TEMA 1029.86Bullish
- TEMA 2029.92Bullish
- TEMA 5030.29Bearish
- MACD0.10Bearish
- ADX20.84Weak Trend
- IndicatorValueSignal
- RSI55.48Neutral
- CCI-11.18Neutral
- ROC 90.03Bullish
- ROC 140.63Bullish
- ROC 251.55Bullish
- Stoch K40.53Neutral
- Stoch D40.71Neutral
- IndicatorValueSignal
- BB Upper30.60Neutral
- BB Middle30.03Neutral
- BB Lower29.46Neutral
- ATR0.65High Volatility
- IndicatorValueSignal
- MFI22.83Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1029.92Bullish
- SMA 2029.85Bullish
- SMA 5029.00Bullish
- EMA 1029.91Bullish
- EMA 2029.71Bullish
- EMA 5029.33Bullish
- DEMA 1030.05Bullish
- DEMA 2030.12Bullish
- DEMA 5029.57Bullish
- TEMA 1029.95Bullish
- TEMA 2030.20Bearish
- TEMA 5029.96Bullish
- MACD0.29Bearish
- ADX30.90Strong Trend
- IndicatorValueSignal
- RSI58.10Neutral
- CCI46.79Neutral
- ROC 91.04Bullish
- ROC 142.72Bullish
- ROC 257.06Bullish
- Stoch K43.53Neutral
- Stoch D46.35Neutral
- IndicatorValueSignal
- BB Upper30.60Neutral
- BB Middle29.85Neutral
- BB Lower29.10Neutral
- ATR0.75Low Volatility
- IndicatorValueSignal
- MFI50.79Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1029.89Bullish
- SMA 2029.16Bullish
- SMA 5029.23Bullish
- EMA 1029.76Bullish
- EMA 2029.44Bullish
- EMA 5029.31Bullish
- DEMA 1030.18Bullish
- DEMA 2029.81Bullish
- DEMA 5029.25Bullish
- TEMA 1030.25Bearish
- TEMA 2030.20Bearish
- TEMA 50N/AN/A
- MACD0.33Bullish
- ADX17.14Weak Trend
- IndicatorValueSignal
- RSI59.44Neutral
- CCI80.05Neutral
- ROC 92.06Bullish
- ROC 147.44Bullish
- ROC 256.12Bullish
- Stoch K75.08Neutral
- Stoch D73.00Neutral
- IndicatorValueSignal
- BB Upper30.82Neutral
- BB Middle29.16Neutral
- BB Lower27.51Neutral
- ATR1.03Low Volatility
- IndicatorValueSignal
- MFI59.61Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1029.05Bullish
- SMA 2028.89Bullish
- SMA 5029.47Bullish
- SMA 10031.10Bearish
- SMA 20042.44Bearish
- EMA 1029.37Bullish
- EMA 2029.23Bullish
- EMA 5029.73Bullish
- EMA 10032.78Bearish
- EMA 20042.96Bearish
- DEMA 1029.74Bullish
- DEMA 2029.21Bullish
- DEMA 5028.16Bullish
- DEMA 10024.31Bullish
- DEMA 20022.14Bullish
- TEMA 1030.13Bearish
- TEMA 2029.49Bullish
- TEMA 5029.57Bullish
- TEMA 10027.85Bullish
- TEMA 20020.03Bullish
- MACD0.04Bullish
- ADX26.40Strong Trend
- IndicatorValueSignal
- RSI58.77Neutral
- CCI109.44Overbought
- ROC 144.05Bullish
- ROC 25-1.70Bearish
- Stoch K75.33Neutral
- Stoch D75.11Neutral
- IndicatorValueSignal
- BB Upper30.21Neutral
- BB Middle28.89Neutral
- BB Lower27.58Neutral
- ATR1.40Low Volatility
- IndicatorValueSignal
- MFI58.77Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 2030.47Bearish
- SMA 5049.36Bearish
- EMA 2032.30Bearish
- EMA 5046.87Bearish
- DEMA 2024.71Bullish
- DEMA 5023.71Bullish
- TEMA 2027.86Bullish
- TEMA 5019.01Bullish
- MACD-5.15Bullish
- ADX24.81Weak Trend
- IndicatorValueSignal
- RSI36.04Neutral
- CCI-65.97Neutral
- ROC 14-12.65Bearish
- ROC 2517.37Bullish
- Stoch K22.16Neutral
- Stoch D27.05Neutral
- IndicatorValueSignal
- BB Upper34.56Neutral
- BB Middle30.47Neutral
- BB Lower26.37Neutral
- ATR3.85Low Volatility
- IndicatorValueSignal
- MFI48.00Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 629.70Bearish
- SMA 1248.90Bearish
- SMA 2476.64Bearish
- EMA 633.63Bearish
- EMA 1246.41Bearish
- EMA 2465.55Bearish
- DEMA 623.77Bullish
- DEMA 1224.01Bullish
- DEMA 2437.84Bearish
- TEMA 626.32Bullish
- TEMA 1219.62Bullish
- TEMA 2423.45Bullish
- MACD-22.56Bearish
- ADX20.33Weak Trend
- IndicatorValueSignal
- RSI38.32Neutral
- CCI-182.37Oversold
- ROC 25-71.76Bearish
- ROC 50-71.91Bearish
- Stoch K7.47Oversold
- Stoch D19.39Oversold
- IndicatorValueSignal
- BB Upper132.45Neutral
- BB Middle68.33Neutral
- BB Lower4.22Neutral
- ATR16.56Low Volatility
- IndicatorValueSignal
- MFI34.60Neutral